Follow
John P. Finnigan, Jr.
John P. Finnigan, Jr.
Brigham and Women's Hospital
Verified email at bwh.harvard.edu - Homepage
Title
Cited by
Cited by
Year
A conserved dendritic-cell regulatory program limits antitumour immunity
B Maier, AM Leader, ST Chen, N Tung, C Chang, J LeBerichel, ...
Nature 580 (7802), 257-262, 2020
2772020
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
F Baharom, RA Ramirez-Valdez, KKS Tobin, H Yamane, CA Dutertre, ...
Nature immunology 22 (1), 41-52, 2021
652021
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative NeoplasmsMut-CALR–Specific Immunity …
C Cimen Bozkus, V Roudko, JP Finnigan, J Mascarenhas, R Hoffman, ...
Cancer discovery 9 (9), 1192-1207, 2019
58*2019
Mutation-derived neoantigen-specific T-cell responses in multiple myeloma
D Perumal, N Imai, A Laganą, J Finnigan, D Melnekoff, VV Leshchenko, ...
Clinical Cancer Research 26 (2), 450-464, 2020
452020
Computational pipeline for the PGV-001 neoantigen vaccine trial
A Rubinsteyn, J Kodysh, I Hodes, S Mondet, BA Aksoy, JP Finnigan, ...
Frontiers in immunology 8, 1807, 2018
412018
TGFβ Receptor 1: An Immune Susceptibility Gene in HPV-Associated CancerIntegrative Analysis of Susceptibility to HPV-Related Cancer
C Levovitz, D Chen, E Ivansson, U Gyllensten, JP Finnigan, S Alshawish, ...
Cancer research 74 (23), 6833-6844, 2014
382014
Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms. Cancer Discov. 2019; 9 …
C Cimen Bozkus, V Roudko, JP Finnigan, J Mascarenhas, R Hoffman, ...
CD-18-1356.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 2020
162020
Mutation-derived tumor antigens: novel targets in cancer immunotherapy
JP Finnigan Jr, A Rubinsteyn, J Hammerbacher, N Bhardwaj
Oncology 29 (12), 970-970, 2015
132015
Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer
JP Finnigan, AG Sikora
Current oncology reports 16 (3), 1-8, 2014
132014
DC Strategies for Eliciting Mutation-derived tumor antigen Responses in Patients
S Balan, J Finnigan, N Bhardwaj
Cancer Journal (Sudbury, Mass.) 23 (2), 131, 2017
92017
Immune checkpoint blockade enhances mutated calreticulin-induced t cell immunity in myeloproliferative neoplasms
CC Bozkus, JP Finnigan, J Mascarenhas, R Hoffman, N Bhardwaj, ...
Blood 130, 384, 2017
6*2017
A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.
A Blazquez, A Rubinsteyn, J Kodysh, JP Finnigan, TU Marron, M Meseck, ...
Journal of Clinical Oncology 37 (15_suppl), e14307-e14307, 2019
22019
Abstract LB048: An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001)
TU Marron, M Saxena, N Bhardwaj, M Meseck, A Rubinsteyn, J Finnigan, ...
Cancer Research 81 (13_Supplement), LB048-LB048, 2021
12021
289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting
T Marron, J Kodysh, A Rubinsteyn, J Finnigan, A Blazquez, M Saxena, ...
Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020
12020
Abstract a022: Computational pipeline for a personalized genomic vaccine trial
A Rubinsteyn, I Hodes, T O'Donnell, SF Mondet, JP Finnigan, ...
Cancer Immunology Research 4 (11_Supplement), A022-A022, 2016
12016
364 Antigen abundance and TCR avidity impact T cell-mediated tumor recognition in novel B16F10 ACT model
J Newman, J Finnigan, A Ishizuka, G Lynn, A Rubinsteyn, T O’Donnell, ...
Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022
2022
Abstract CT173: PGV-001: A phase I trial of a multipeptide personalized neoantigen vaccine in the adjuvant setting
J Kodysh, T Marron, A Rubinsteyn, T O'Donnell, J Finnigan, A Blazquez, ...
Cancer Research 80 (16_Supplement), CT173-CT173, 2020
2020
A conserved dendritic-cell regulatory program limits antitumour immunity (vol 580, pg 257, 2020)
B Maier, AM Leader, ST Chen, N Tung, C Chang, J LeBerichel, ...
NATURE 582 (7813), E17-E17, 2020
2020
A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers
AB Blazquez, A Rubinsteyn, J Kodysh, JP Finnigan, T Marron, RL Sabado, ...
CANCER IMMUNOLOGY RESEARCH 7 (2), 2019
2019
Abstract A005: A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers
AB Blazquez, A Rubinsteyn, J Kodysh, JP Finnigan, T Marron, RL Sabado, ...
Cancer Immunology Research 7 (2_Supplement), A005-A005, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20